Research Topics
Genomes and GenesSpecies | A C W ZannettinoSummaryAffiliation: South Australia Country: Australia Publications
| Collaborators
|
Detail Information
Publications
An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factorsAndrew C W Zannettino
Myeloma and Mesenchymal Research Laboratory, Institute of Medical and Veterinary Science, Adelaide, Australia
Methods Mol Med 113:245-56. 2005..This chapter describes one such in vitro model system...- Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patientsHelen Tsangari
Bone and Joint Research Laboratory, Division of Tissue Pathology, Institute of Medical and Veterinary Science, Hanson Institute, and the University of Adelaide, Frome Road, Adelaide 5000, Australia
Bone 39:1226-35. 2006..These data suggest that perturbations in bone formation surface, relative to resorption surface, are potentially important in producing bone in the proximal femur with increased propensity to fracture... - The role of the chemokine CXCL12 in osteoclastogenesisStan Gronthos
Mesenchymal Stem Cell Group, Division of Haematology, Institute of Medical and Veterinary Science, Hanson Institute, Adelaide, South Australia, Australia
Trends Endocrinol Metab 18:108-13. 2007..Recent studies have highlighted an emerging role for CXCL12 in the processes of physiological and pathological bone remodelling... 
Pentosan polysulfate promotes proliferation and chondrogenic differentiation of adult human bone marrow-derived mesenchymal precursor cellsPeter Ghosh
Proteobioactives Pty Ltd, 27 9 Powells Road, Brookvale, New South Wales 2100, Australia
Arthritis Res Ther 12:R28. 2010..This study was undertaken to determine whether the anti-osteoarthritis drug pentosan polysulfate (PPS) influenced mesenchymal precursor cell (MPC) proliferation and differentiation...- The sialomucin CD164 (MGC-24v) is an adhesive glycoprotein expressed by human hematopoietic progenitors and bone marrow stromal cells that serves as a potent negative regulator of hematopoiesisA C Zannettino
Hanson Centre for Cancer Research, Matthew Roberts Laboratory, Institute of Medical and Veterinary Science, Adelaide, Australia
Blood 92:2613-28. 1998.... - Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patientsAndrew C W Zannettino
Myeloma and Mesenchymal Research Group, Matthew Roberts Foundation Laboratory and Mesenchymal Stem Cell Group, Division of Haematology, Institute of Medical and Veterinary Science, Hanson Institute, Adelaide, Australia
Cancer Res 65:1700-9. 2005..Therefore, we propose that inhibition of the CXCR4-SDF-1alpha axis may provide an effective means of treatment for MM-induced osteolysis... - Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factorA C W Zannettino
Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, and Hanson Institute, Adelaide, South Australia, Australia
J Cell Physiol 204:714-23. 2005.... - Molecular cloning of the cell surface antigen identified by the osteoprogenitor-specific monoclonal antibody, HOP-26Andrew C W Zannettino
Myeloma and Mesenchymal Research Laboratory, Hanson Centre for Cancer Research, I M V S, PO Box 14, Rundle Mall, Adelaide 5000, South Australia, Australia
J Cell Biochem 89:56-66. 2003..Western blot analysis of human bone marrow stromal cells (HBMSC) has revealed that like a well defined CD63 mAb 12F12, HOP-26 interacts with a heavily glycosylated cell surface protein with an apparent molecular weight of 50-60 kD... - CD164A C Zannettino
Division of Haematology, Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
J Biol Regul Homeost Agents 15:394-6. 2001 
Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populationsP J Psaltis
Centre for Stem Cell Research, Robinson Institute and Department of Medicine, University of Adelaide, South Australia, Australia
J Cell Physiol 223:530-40. 2010..Immunoselection thus provides a strategy for improving the cardiovascular reparative potential of mesenchymal cells...- Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free mediumGerald J Atkins
Department of Orthopaedics and Trauma, University of Adelaide, and the Hanson Institute, Adelaide, South Australia, Australia
J Cell Physiol 203:573-82. 2005..This study demonstrates that under the appropriate conditions, adult human primary osteoblasts can support de novo osteoclast formation, and this model will enable the detailed study of the role of both cell types in this process... - Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosisG J Atkins
Department of Orthopaedics and Trauma, Adelaide University and Royal Adelaide Hospital, Adelaide, SA, Australia
Bone 31:448-56. 2002..In addition, they predict that therapeutic use of recombinant Apo2L/TRAIL, in combination with chemotherapeutic agents to treat skeletal malignancies, would have limited toxic effects on normal osteoblastic cells... - Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivoA C W Zannettino
Myeloma Research Program, Bone and Cancer Laboratories, Division of Haematology, Institute of Medical and Veterinary Science, Hanson Institute and University of Adelaide, Adelaide, Australia
J Cell Physiol 214:413-21. 2008..The findings presented here, describe a multipotential stem cell population within adult human adipose tissue, which appear to be intimately associated with perivascular cells surrounding the blood vessels... - Imatinib as a potential antiresorptive therapy for bone diseaseAndrea L Dewar
Division of Haematology, Institute of Medical and Veterinary Science, Frome Rd, Adelaide 5000, Australia
Blood 107:4334-7. 2006..These results suggest that imatinib may have therapeutic value as an antiosteolytic agent in diseases such as osteoporosis, metastatic bone disease, and multiple myeloma... - RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of boneGerald J Atkins
Department of Orthopaedics and Trauma, University of Adelaide, Adelaide, South Australia, Australia
J Bone Miner Res 21:1339-49. 2006..The ability to reliably detect committed pre-OC in peripheral blood could have important clinical applications in the management of diseases characterized by abnormal osteoclastic activity... - The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivoKate Vandyke
Myeloma Research Laboratory, Department of Haematology, Centre for Cancer Biology, Institute of Medical and Veterinary Science, Adelaide, Australia
J Bone Miner Res 25:1759-70. 2010..These studies show that dasatinib increases trabecular bone volume at least in part by inhibiting osteoclast activity, suggesting that dasatinib therapy may result in dysregulated bone remodeling... - The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myelomaS K Martin
Division of Haematology, Centre for Cancer Biology, SA Pathology, CSCR, University of Adelaide, Adelaide, South Australia
Leukemia 25:1533-42. 2011..The need for current and future therapeutic interventions to target HIF-1 and HIF-2 in myeloma will also be discussed... - Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activityJ R Engler
Department of Haematology, SA Pathology RAH Campus, Adelaide, South Australia, Australia
Leukemia 24:765-70. 2010..These results indicate that low imatinib accumulation in primitive CML cells, mediated through reduced OCT-1 Activity may be a critical determinant of long-term disease persistence... - Methods for the purification and characterization of human adipose-derived stem cellsStan Gronthos
Mesenchymal Stem Cell Group, Department of Haematology, Institute of Medical and Veterinary Science Hanson Institute and Centre for Stem Cell Research, University of Adelaide, Adelaide, SA, Australia
Methods Mol Biol 702:109-20. 2011.... - Concise review: mesenchymal stromal cells: potential for cardiovascular repairPeter J Psaltis
Cardiovascular Research Centre, Royal Adelaide Hospital and Department of Medicine, University of Adelaide, Adelaide, South Australia 5000, Australia
Stem Cells 26:2201-10. 2008.... - Dysregulation of bone remodeling by imatinib mesylateKate Vandyke
Myeloma and Mesenchymal Research Laboratory, Division of Haematology, Centre for Cancer Biology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, Australia
Blood 115:766-74. 2010..The potential application of imatinib in the treatment of cancer-induced osteolysis will also be discussed... - A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cellsStan Gronthos
Mesenchymal Research Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, Hanson Institute and University of Adelaide, Australia 5000
Stem Cells Dev 16:953-63. 2007..Finally, these studies suggest that antibodies to TNSALP may be used as an effective single marker of enrichment of BMSSCs from various tissues... - Genomic profiling of mesenchymal stem cellsDanijela Menicanin
Mesenchymal Stem Cell Group, Bone and Cancer Laboratories, Division of Haematology, Institute of Medical and Veterinary Science Hanson Institute and CSCR, University of Adelaide, SA, Australia
Stem Cell Rev 5:36-50. 2009..The present review summarizes studies characterizing the gene expression profile of MSCs... - Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrowStan Gronthos
Mesenchymal Stem Cell Group, Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
J Cell Sci 116:1827-35. 2003..Our novel selection protocol provides a means to generate purified populations of BMSSCs for use in a range of different tissue engineering and gene therapy strategies... - OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibDeborah L White
Division of Hematology, Institute of Medical and Veterinary Science IMVS and Hanson Institute, Adelaide, South Australia
Blood 108:697-704. 2006..Determining interpatient and interdrug differences in cellular uptake and retention could allow individual optimization of kinase inhibitor therapy... - Inhibition of c-fms by imatinib: expanding the spectrum of treatmentAndrea L Dewar
Division of Haematology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia
Cell Cycle 4:851-3. 2005..We also speculate that imatinib may be used in diseases where bone destruction occurs due to excessive osteoclast activity, such as in the haematologic malignancy, multiple myeloma... - Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibAndrea L Dewar
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
Blood 105:3127-32. 2005..Imatinib should now be assessed for activity in diseases where c-fms activation is implicated, including breast and ovarian cancer and inflammatory conditions... - TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitmentSandra Isenmann
Mesenchymal Stem Cell Group, Division of Haematology, Institute of Medical and Veterinary Science Hanson Institute CSCR, University of Adelaide, SA, Australia
Stem Cells 27:2457-68. 2009..These findings implicate the TWIST gene family members as potential mediators of MSC self-renewal and lineage commitment in postnatal skeletal tissues by exerting their effects on genes involved in the early stages of bone development... - Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaAgatha Labrinidis
Discipline of Orthopaedics and Trauma, The University of Adelaide, Royal Adelaide Hospital, and Hanson Institute, South Australia, Australia
Clin Cancer Res 15:1998-2009. 2009..Here, we report on the efficacy of recombinant soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to inhibit tumor progression and bone destruction in a xenogeneic model of human multiple myeloma... - Long-term imatinib therapy promotes bone formation in CML patientsStephen Fitter
Bone and Cancer Research Laboratories, and Division of Haematology, Institute of Medical and Veterinary Science IMVS, The Hanson Institute, Adelaide, SA 5000, Australia
Blood 111:2538-47. 2008..Further investigation is required to determine whether the increase in TBV associated with imatinib therapy may represent a novel therapeutic avenue for the treatment of diseases that are characterized by generalized bone loss... - Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34 /CD45(-)/glycophorin-A-bone marrow cellsAndrew C W Zannettino
Multiple Myeloma Research Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, Hanson Institute and University of Adelaide, Australia
Haematologica 92:1707-8. 2007..These studies support the view that these are two distinct stem cell compartments in adult bone marrow... - Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?Stephen Fitter
Myeloma Research Laboratory, Department of Hematology, Centre for Cancer Biology, Institute of Medical and Veterinary Science, G P O Box 14, Adelaide, South Australia 5000, Australia
J Clin Endocrinol Metab 95:3763-7. 2010..The mechanism(s) by which imatinib improves glycemic control in chronic myeloid leukemia (CML) patients with type 2 diabetes remains unclear... - RANKL expression is related to the differentiation state of human osteoblastsGerald J Atkins
Department of Orthopaedics and Trauma, University of Adelaide, Adelaide, South Australia, Australia
J Bone Miner Res 18:1088-98. 2003..Additionally, the dual roles of osteoblasts, in supporting osteoclastogenesis or forming bone, may be performed by the same lineage of cells at different stages of their maturation... - Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myelomaSally K Martin
Myeloma and Mesenchymal Research Group, Matthew Roberts Foundation Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, University of Adelaide, Australia
Clin Cancer Res 12:6973-7. 2006..Therefore, we propose that inhibition of SDF-1alpha may be an effective mechanism by which angiogenesis and osteolysis can be reduced in multiple myeloma patients... - Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivoAmanda N Farrugia
Myeloma and Mesenchymal Research Group, Matthew Roberts Foundation Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia
Cancer Res 63:5438-45. 2003.... - Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone lossPeter Diamond
Myeloma Research Program, Bone and Cancer Laboratories, Division of Haematology, Institute of Medical and Veterinary Science, Hanson Institute and the Department of Medicine, University of Adelaide, Adelaide, Australia
J Bone Miner Res 24:1150-61. 2009..These findings confirm our hypothesis that MM PC-derived CXCL12 stimulates the recruitment and activity of OC, thereby contributing to the formation of MM osteolytic lesions... - The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitroBeiqing Pan
Myeloma and Mesenchymal Research Group, Matthew Roberts Foundation Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, Adelaide 5000, Australia
Bone 34:112-23. 2004..These results show that, in addition to its direct effects on OCs, ZOL also directly affects the proliferation and differentiation of human OB-like cells in vitro and may enhance bone formation in vivo... - A method to isolate and purify human bone marrow stromal stem cellsStan Gronthos
Mesenchymal Stem Cell Group, Division of Haematology, Institute of Medical and Veterinary Science, Hanson Institute, University of Adelaide, SA, Australia
Methods Mol Biol 449:45-57. 2008.... - Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancerIrene Zinonos
Discipline of Orthopaedics and Trauma Level 4, Bice Building, Royal Adelaide Hospital, North Terrace, Adelaide 5000, South Australia, Australia
Mol Cancer Ther 8:2969-80. 2009..Apomab represents a potent immunotherapeutic agent with strong activity against the development and progression of breast cancer and should be evaluated in patients with primary and metastatic disease... - Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migrationAndrew C W Zannettino
Myeloma and Mesenchymal Research Group, Matthew Roberts Laboratory, Hanson Centre for Cancer Research, I M V S, Adelaide 5000, Australia
Biochem J 370:537-49. 2003..These observations will be instrumental in determining the mechanisms whereby PZR isoforms regulate cell motility... - CD36/fatty acid translocase in rats: distribution, isolation from hepatocytes, and comparison with the scavenger receptor SR-B1Xingqi Zhang
The Arthritis Research Laboratory, Hanson Centre for Cancer Research, Adelaide, South Australia, Australia
Lab Invest 83:317-32. 2003..We suggest that CD36/FAT might function in the liver as a sex-regulated accessory molecule, either in reverse cholesterol transport and/or in fatty acid uptake... - Home is where the heart is: via the FROUNTAndrew C W Zannettino
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
Cell Stem Cell 2:513-4. 2008..This process is dependent on the intracellular adaptor molecule FROUNT, which interacts with the chemokine receptor CCR2... - Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3Gerald J Atkins
Department of Orthopaedics and Trauma, University of Adelaide, Adelaide, South Australia 5000, Australia
Bone 40:1517-28. 2007..Our results are therefore consistent with the reported benefits of maintaining a healthy vitamin D status in the elderly to reduce the risk of fractures... - The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE)Beiqing Pan
Myeloma and Mesenchymal Research Group, Matthew Robert Foundation Laboratory, Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
J Bone Miner Res 19:147-54. 2004..CONCLUSIONS: Our studies indicate that ZOL, in addition to its direct effects on mature OCs, may inhibit the recruitment and differentiation of OCs by cleavage of transmembrane RANKL in OB-like cells by upregulating the sheddase, TACE... - The proliferation and phenotypic expression of human osteoblasts on tantalum metalDavid M Findlay
Department of Orthopaedics and Trauma, University of Adelaide, South Australia
Biomaterials 25:2215-27. 2004..No substrate-dependent differences were seen in the extent of in vitro mineralisation by NHBC. These results indicate that Ta is a good substrate for the attachment, growth and differentiated function of human osteoblasts... - Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclastsYun Shan Hu
Bone, Joint, and Cancer Unit, St Vincent s Institute of Medical Research, Fitzroy, Victoria, Australia
J Bone Miner Res 19:89-99. 2004..OCIL shows promise as a new antiresorptive... - Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis?Agatha Labrinidis
Blood 111:5411-2; autor reply 5413. 2008